Research programme: single domain antibody therapeutics - AdAlta

Drug Profile

Research programme: single domain antibody therapeutics - AdAlta

Alternative Names: AD 114; i-bodies

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator AdAlta
  • Developer AdAlta; Lonza
  • Class Antibodies; Antifibrotics; Proteins
  • Mechanism of Action G protein-coupled receptor modulators; Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Idiopathic pulmonary fibrosis
  • Research Fibrosis; Retinal disorders

Most Recent Events

  • 21 Mar 2017 AdAlta and the Alfred Hospital expand collaboration to co-develop AD 114 in Australia for Idiopathic pulmonary fibrosis
  • 18 Jan 2017 AD 114 receives Orphan Drug status for Idiopathic pulmonary fibrosis in USA
  • 09 Jan 2017 Pharmacodynamics data from a preclinical trial in Idiopathic pulmonary fibrosis released by AdAlta
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top